Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Moderate Buy” from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $9.43.

A number of equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price objective (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Finally, Stephens began coverage on Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company.

Pyxis Oncology Price Performance

Shares of PYXS stock opened at $1.53 on Tuesday. Pyxis Oncology has a 1-year low of $1.48 and a 1-year high of $6.85. The firm has a market cap of $90.98 million, a PE ratio of -1.49 and a beta of 1.06. The company has a 50-day moving average of $2.30 and a two-hundred day moving average of $3.08.

Insiders Place Their Bets

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was acquired at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the purchase, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.80% of the stock is owned by company insiders.

Institutional Trading of Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new position in Pyxis Oncology during the 3rd quarter worth approximately $55,000. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth $58,000. The Manufacturers Life Insurance Company acquired a new position in shares of Pyxis Oncology during the second quarter worth $65,000. MetLife Investment Management LLC increased its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Pyxis Oncology in the third quarter valued at $107,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.